Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several positive aspects: a significant reduction in net loss, gains from asset sales, and a promising new formulation of enobosarm with extended patent protection. While there are concerns about increased cash use and unclear management responses, the overall strategic direction, market potential, and regulatory flexibility provide a positive outlook, likely resulting in a 2% to 8% stock price increase.
Key Financial Performance
Cash and Cash Equivalents As of September 30, 2025, the cash and cash equivalents and restricted cash balance was $15.8 million, compared to $24.9 million as of September 30, 2024, representing a decrease. The decrease is attributed to the company's operating expenses and investments in drug development.
Net Proceeds from Public Offering On October 31, 2025, the company completed a public offering resulting in net proceeds of approximately $23.4 million. This was used to support the company's operations and drug development programs.
Research and Development Costs Increased to $15.6 million in fiscal 2025 from $12.8 million in the prior year, representing a year-over-year increase. The increase is due to expenses related to the Phase IIb QUALITY clinical study for enobosarm.
Selling, General and Administrative Expenses Decreased to $19.9 million in fiscal 2025 from $24.6 million in the prior year, representing a year-over-year decrease. The decrease is primarily due to reduced share-based compensation expenses.
Net Loss from Continuing Operations For fiscal 2025, the net loss was $15.7 million or $1.07 per diluted common share, compared to a net loss of $35.3 million or $2.61 per diluted common share in the prior year. The improvement is due to gains from the sale of assets and reduced operating expenses.
Net Loss from Discontinued Operations For fiscal 2025, the net loss was $7 million or $0.48 per diluted common share, compared to $2.5 million or $0.19 per diluted common share in the prior year. The increase is due to the loss on the sale of the FC2 Female Condom business and reduced gross profit.
Gain on Sale of ENTADFI Assets Recognized a gain of $10.8 million in fiscal 2025, compared to $1.2 million in the prior year. The increase is due to nonrefundable consideration received related to promissory notes.
Cash Used in Operating Activities Used $30 million for operating activities in fiscal 2025, compared to $21.7 million in the prior year, representing an increase. The increase is due to higher operating expenses and investments in drug development.
Cash Generated from Investing Activities Generated $25.1 million in fiscal 2025, compared to $0.1 million in the prior year. The increase is due to proceeds from the sale of the FC2 Female Condom business and ENTADFI assets.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Enobosarm: An oral selective androgen receptor modulator (SARM) developed to enhance weight reduction by GLP-1 receptor agonist drugs, focusing on fat loss while preserving lean mass. Phase IIb clinical trial results showed 100% lean mass preservation and 12% greater fat loss compared to placebo. It also demonstrated improved physical function and reduced weight regain after discontinuation of semaglutide.
Sabizabulin: A microtubule disruptor being developed as a broad anti-inflammatory agent to reduce vascular plaque inflammation and slow the progression of atherosclerotic cardiovascular disease.
Obesity Drug Market: Targeting older patients with obesity, especially those with a BMI ≥ 35 and aged ≥ 65. The company plans to address the weight loss plateau observed in GLP-1 receptor agonist treatments with a combination therapy of enobosarm and GLP-1 receptor agonists.
Financial Position: Cash and cash equivalents as of September 30, 2025, were $15.8 million. A public offering in October 2025 raised $23.4 million. The company plans to use these funds to support the Phase IIb PLATEAU clinical study.
Sale of FC2 Female Condom Business: The business was sold for $18 million, with net proceeds of $16.5 million. This sale represents a strategic shift to focus exclusively on drug development.
Strategic Focus: Shifted focus exclusively to drug development by selling the FC2 Female Condom business and reallocating resources to the development of enobosarm and sabizabulin.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Challenges: The regulatory landscape for muscle preservation drugs in obesity treatment is evolving, and Veru must navigate FDA guidance for enobosarm's approval. This includes meeting specific efficacy endpoints, such as incremental weight loss or clinically significant benefits, which could delay or complicate the approval process.
Financial Constraints: Veru reported a net loss of $15.7 million from continuing operations and $7 million from discontinued operations in fiscal 2025. The company is not profitable, has negative cash flow from operations, and will require additional capital to fund its drug development programs, posing a risk to its financial stability.
Market Competition: The obesity drug market is highly competitive, with major players like Eli Lilly, Versanis, Scholar Rock, and Regeneron also developing treatments. This competitive pressure could impact Veru's market share and revenue potential.
Supply Chain and Operational Risks: The company has shifted its focus entirely to drug development after selling its FC2 Female Condom business. This strategic shift may introduce operational risks as Veru transitions to a single focus on biopharmaceuticals.
Clinical Development Risks: The success of Veru's enobosarm and sabizabulin programs depends on positive clinical trial outcomes. Any setbacks in these trials could adversely affect the company's strategic objectives and financial performance.
Economic Uncertainty: The company’s reliance on public offerings and external funding makes it vulnerable to economic fluctuations, which could impact its ability to raise necessary capital.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Enobosarm Clinical Development Plan: The FDA has provided two regulatory pathways for enobosarm in combination with GLP-1 receptor agonists: (1) achieving at least a 5% placebo-corrected weight loss difference at 52 weeks of maintenance treatment, or (2) demonstrating clinically significant benefits such as preservation of physical function even with less than 5% incremental weight loss. The next study, Phase IIb PLATEAU clinical trial, will target patients with obesity (BMI ≥ 35) and aged ≥ 65 to assess enobosarm's ability to break through weight loss plateaus. The trial will evaluate total body weight change, physical function, and safety over 72 weeks, with an interim analysis at 36 weeks. The study is expected to begin in Q1 2026, with interim results anticipated in Q1 2027.
Phase IIb QUALITY Clinical Trial Results: The trial demonstrated that enobosarm 3 mg combined with semaglutide preserved 100% lean mass and achieved 12% greater fat loss compared to semaglutide alone over 16 weeks. Enobosarm also reduced the proportion of patients experiencing physical function decline by 59.8%. During the maintenance phase, enobosarm monotherapy significantly reduced weight regain by 46% and preserved lean mass. The drug showed a positive safety profile with no significant adverse events.
Market Opportunity and Strategic Focus: The company plans to target the growing population of patients experiencing weight loss plateaus with GLP-1 receptor agonists. Enobosarm is positioned as a complementary therapy to address this unmet need, potentially reducing the need for bariatric surgery and improving outcomes for patients with obesity.
Financial Position and Funding: As of September 30, 2025, the company had $15.8 million in cash and cash equivalents, with an additional $23.4 million raised through a public offering in October 2025. This funding is expected to support operations through the interim analysis of the Phase IIb PLATEAU clinical trial.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Will any GLP-1 be allowed in your Phase IIb study, or will it be limited to just tirzepatide?
A:The study will include either tirzepatide or semaglutide, but not both, to avoid variability. The placeholder is currently tirzepatide, but it could change to semaglutide.
Q:How does the Phase I to Phase III transition work, and will the FDA allow a functional endpoint like strength as a primary endpoint in Phase III?
A:The Phase IIb study is designed to mimic a mini Phase III, focusing on incremental weight loss as the primary endpoint and functional endpoints as key secondary endpoints. The FDA has provided flexibility, allowing functional endpoints to serve as primary endpoints if incremental weight loss is not achieved.
Q:Why is the PLATEAU study targeting patients over 65, and is this based on FDA guidance or other factors?
A:The study targets patients over 65 because they are the most in need, often having sarcopenia and physical limitations. This approach aligns with FDA guidance and ensures the study focuses on the right patient population for functional endpoints.
Q:What are the expected outcomes and regulatory flexibility for the PLATEAU study regarding weight loss and muscle function?
A:The study aims for a 5% or greater placebo-corrected weight loss as a benchmark. Multiple physical function tests and clinical outcomes will be used to demonstrate clinical meaningfulness, providing flexibility in regulatory discussions.
Q:What is the significance of the new formulation of enobosarm and its intellectual property?
A:The new formulation of enobosarm extends patent protection to 2046, ensuring exclusivity for the Phase III and commercial use. Enobosarm is a new chemical entity with robust intellectual property protection.
Q:What are the potential market opportunities for enobosarm?
A:Enobosarm targets a large market, including 44 million Americans on Medicare Part D, half of whom could benefit from a weight loss drug. It also has potential for combination therapy with oral agents being developed by big pharma.
Q:What are the key learnings from the competitive landscape and FDA feedback?
A:Competitors' data showed the importance of holding onto lean mass for incremental weight loss. The FDA provided flexibility, allowing functional endpoints to be included in the label, enhancing the drug's regulatory pathway.
Q:What are the next steps and overall outlook for the program?
A:The program is well-positioned with funding, intellectual property, and a robust trial design. The focus is on derisking the program and exploring multiple regulatory pathways to maximize opportunities.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific degree of weight loss required for regulatory approval beyond the 5% benchmark and used vague language when discussing the flexibility of functional endpoints in regulatory discussions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BMI weight
DEXA scan
FC Female
Female Condom
GLP receptor
IIb PLATEAU
IIb QUALITY
PLATEAU trial
Phase IIb
QUALITY study
Series warrant
activity cash
class
climb power
combination GLP
company Phase
decline stair
end week
enobosarm combination
enobosarm milligram
generation
loss period
loss plateau
loss week
maintenance treatment
mass DEXA
milligram group
milligram treatment
offering
placebo monotherapy
plateau weight
safety profile
semaglutide milligram
share stock
stock Series
warrant share
week weight
VERU Transcript
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
Unknown5-13
The earnings call summary reflects a negative sentiment due to declining revenue, decreased gross margin, and reduced net income, all of which are concerning for investors. The increased R&D expenses, while potentially beneficial in the long term, contribute to the current financial strain. The absence of strategic initiatives or positive guidance further exacerbates the negative outlook. Additionally, the lack of clarity in management's responses during the Q&A session adds to investor uncertainty, likely leading to a negative stock price movement in the short term.
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Unknown2-11
The earnings call presents a mixed picture. While there are positive developments in clinical trials and financial improvements, significant risks and challenges remain. The regulatory hurdles for enobosarm, bone density concerns, and intense market competition could weigh on investor sentiment. The Q&A session did not reveal any new risks, but the lack of profitability and the need for clear market advantages are concerns. The financial position shows improved cash reserves, but sustainability is uncertain. These factors balance each other out, leading to a neutral sentiment rating.
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Positive12-17
The earnings call highlights several positive aspects: a significant reduction in net loss, gains from asset sales, and a promising new formulation of enobosarm with extended patent protection. While there are concerns about increased cash use and unclear management responses, the overall strategic direction, market potential, and regulatory flexibility provide a positive outlook, likely resulting in a 2% to 8% stock price increase.
Veru Inc. (VERU) Q3 2025 Earnings Call Transcript
Unknown8-12
The earnings call summary and Q&A indicate mixed signals. While the company shows progress in drug development and partnership discussions, financial health raises concerns due to insufficient cash for long-term operations and a significant net loss. The potential for new partnerships and an improved formulation could be positive, but financial constraints and the need for substantial capital for Phase III trials temper expectations. The market is likely to react cautiously, resulting in a neutral sentiment.
VERU Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
